Physician profile
Michael Logsdon
NPI 1669855235
$1,918.61
in general payments reported to CMS, 2019-2025
23 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $51.12 · 2024: $932 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $626.75 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $241.81 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $152.25 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $123.69 | 2024-2025 | |
| Glaxosmithkline, LLC. | $121.22 | 2024-2025 | Bexsero, Arexvy, Shingrix |
| Novo Nordisk INC | $114.95 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $83.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.13 | 2024-2025 | Jardiance |
| Seqirus USA INC | $48.43 | 2024-2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $42.01 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $38.67 | 2024-2025 | Voquezna |
| Amgen INC. | $36.64 | 2023-2024 | Repatha, Otezla, Prolia |
| Idorsia Pharmaceuticals US INC | $31.98 | 2024-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $27.84 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $26.53 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.00 | 2025 | Xifaxan |
| Braeburn INC. | $24.04 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.90 | 2025 | Caplyta |
| Indivior INC. | $22.54 | 2025 | Sublocade |
| Dexcom, INC. | $16.38 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.22 | 2025 | Auvelity |
| Snap Diagnostics LLC | $12.20 | 2023 | Snap Diagnostics Study |
| Organon LLC | $11.66 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Logsdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.